HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs.

To view the full press release, visit https://ibn.fm/yN939

At a glance

Company: HeartBeam, Inc.
Ticker: NASDAQ: BEAT
Announcement: Earnings

Key figures

Conference call date: May 13, 2026
Conference call time: 4:30 p.m. Eastern time
Quarter-end date: March 31, 2026
Issued patents: over 20

Products and programs

3D ECG technology
Arrhythmia assessment offering
Extended-wear patch
Heart attack detection program
AI programs
12-lead ECG synthesis software

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Questions around this news

When is HeartBeam's Q1 2026 earnings call, and what will it cover?
The conference call is scheduled for May 13, 2026, at 4:30 p.m. Eastern time. HeartBeam plans to discuss its first-quarter results for the period ended March 31, 2026, and provide updates on several growth initiatives. The release does not provide call-in details or say whether a replay will be available.
Which initiatives will HeartBeam discuss on the call?
The company says it will update listeners on a limited commercial launch for arrhythmia assessment, development of an extended-wear patch, heart attack detection, and artificial intelligence programs. The release identifies these as key growth initiatives but does not describe their timelines, commercial terms, or development milestones.
How does HeartBeam describe its 3D ECG technology?
The release describes a cable-free device that collects electrocardiogram signals from three directions that are not in the same plane, then uses software to synthesize them into a 12-lead ECG. The platform is designed for portable devices intended to be used outside medical facilities. The release says the technology is intended to support cardiac monitoring and detection.

SEC filings

Earlier from HeartBeam, Inc.

Back to News Center